Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | PRKX | P51817 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440111 | 0.78 | MAPT (0.46) | — | |
| SCHEMBL15544686 | 0.77 | TLR8 (0.44) | ADORA2AADORA1ADORA2B | |
| SCHEMBL7071992 | 0.74 | PIK3CD (0.31) | — | |
| SCHEMBL7077149 | 0.74 | HPGDS (0.31) | — | |
| SCHEMBL2000051 | 0.72 | LRRK2 (0.41) | — | |
| SCHEMBL7073225 | 0.69 | ADORA3 (0.30) | ADORA2AADORA3 | |
| SCHEMBL1551877 | 0.68 | ADORA2A (0.42) | ADORA2AADORA1IGF1RFGFR1LTK | |
| SCHEMBL15545185 | 0.68 | ADORA2A (0.42) | ADORA2AADORA1IGF1RFGFR1LTK | |
| SCHEMBL19027634 | 0.66 | — | — | |
| SCHEMBL7072307 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209035-A1 | POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2024-06-27 | — | — | US | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4323382-A1 | POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF | Biorchestra Co., Ltd. (KR) | 2024-02-21 | — | — | EP | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| CN-117500822-A | Polynucleotide capable of enhancing protein expression and use thereof | 生物欧赛加有限责任公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2024026490-A1 | POLYNUCLEOTIDES ENCODING LINKED ANTIGENS AND USES THEREOF | SQZ BIOTECHNOLOGIES COMPANY (US) | 2024-02-01 | — | — | WO | claimed |
| EP-4274846-A1 | EXPRESSION CONSTRUCTS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023212618-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2023-11-02 | — | — | WO | claimed |
| CN-116917309-A | Expression constructs and uses thereof | 斯特兰德生物科技公司 | 2023-10-20 | — | — | CN | claimed |
| US-20230295257-A1 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | STRAND THERAPEUTICS INC. (US) | 2023-09-21 | — | — | US | claimed |
| CN-116710079-A | Lipid nanoparticles comprising modified nucleotides | 斯特兰德生物科技公司 | 2023-09-05 | — | — | CN | claimed |
| EP-4185274-A1 | LIPIDNANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | Strand Therapeutics Inc. (US) | 2023-05-31 | — | — | EP | claimed |
| WO-2022150712-A1 | EXPRESSION CONSTRUCTS AND USES THEREOF | STRAND THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | claimed |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| WO-2012045075-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | SCHRUM JASON (US) | 2012-04-05 | — | — | WO | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209035-A1 | POLYNUCLEOTIDES CAPABLE OF ENHANCED PROTEIN EXPRESSION AND USES THEREOF | UPF1, PABPC4, NSUN3 | ADORA2A 3917/4885ADORA1 4740/4885NTRK1 1771/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ADORA2A 399/4885ADORA1 840/4885NTRK1 3375/4885 |
| US-20230295257-A1 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | CASP12, RNMT, RBM12 | ADORA2A 1477/4885ADORA1 2162/4885NTRK1 4224/4885 |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | RNMT, RNGTT, NSUN3 | ADORA2A 381/4885ADORA1 202/4885NTRK1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.